Evaluation of cholesterol depletion as a marker of nephrotoxicity in vitro for novel β-cyclodextrin derivatives

Food and Chemical Toxicology

Volumn 49, Issue 6, 2011, Pages 1387-1393

  Wang, Hui ^a   Xie, Xiaoxia ^a   Zhang, Fengyi ^a   Zhou, Qian ^a   Tao, Qing ^a   Zou, Yina ^a   Chen, Cheng ^a   Zhou, Chengliang ^a   Yu, Shuqin ^a  

^a NANJING NORMAL UNIVERSITY   (China)

Author keywords

Cell membranes; Cholesterol depletion; Cyclodextrin derivatives; HPn SBEm CD; LDH; Nephrotoxicity

Indexed keywords

2,6 O DIMETHYL BETA CYCLODEXTRIN; BETA CYCLODEXTRIN DERIVATIVE; BETA CYCLODEXTRIN SULFOBUTYL ETHER; CHOLESTEROL; HYDROXYPROPYL SULFOBUTYL ETHER BETA CYCLODEXTRIN DERIVATIVE; LACTATE DEHYDROGENASE; METHYL BETA CYCLODEXTRIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL MEMBRANE; CELL STRAIN HEK293; CELL STRUCTURE; CELL ULTRASTRUCTURE; CELL VIABILITY; CHEMICAL STRUCTURE; CHOLESTEROL DEPLETION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DEPLETION; EMBRYO; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; MEMBRANE DAMAGE; NEPHROTOXICITY;

APOPTOSIS; BETA-CYCLODEXTRINS; BIOLOGICAL MARKERS; CELL MEMBRANE; CELL NUCLEUS; CELL SURVIVAL; CHOLESTEROL; FLOW CYTOMETRY; HEK293 CELLS; HUMANS; KIDNEY; KIDNEY DISEASES; L-LACTATE DEHYDROGENASE; NECROSIS;

EID: 79955662932     PISSN: 02786915     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fct.2011.03.026     Document Type: Article

References (42)

1. Ahmed S.N., Brown D.A., London E. On the origin of sphingolipid/cholesterol-rich detergent-insoluble cell membranes: physiological concentrations of cholesterol and sphingolipid induce formation of a detergent-insoluble, liquid-ordered lipid phase in model membranes. Biochemistry 1997, 36:10944-10953.
2. Anderson R.G., Jacobson K. A role for lipid shells in targeting proteins to caveolae, rafts, and other lipid domains. Science 2002, 296:1821-1825.
3. Barenholz Y. Sphingomyelin and cholesterol: from membrane biophysics and rafts to potential medical applications. Subcell Biochem. 2004, 37:167-215.
4. Brewster M.E., Loftsson T. Cyclodextrins as pharmaceutical solubilizers. Adv. Drug Deliv. Rev. 2007, 59:645-666.
5. Brown D.A., London E. Functions of lipid rafts in biological membranes. Annu. Rev. Cell Dev. Biol. 1998, 14:111-136.
6. Burger K., Gimpl G., Fahrenholz F. Regulation of receptor function by cholesterol. Cell Mol. Life Sci. 2000, 57:1577-1592.
7. Crane J.M., Tamm L.K. Role of cholesterol in the formation and nature of lipid rafts in planar and spherical model membranes. Biophys. J. 2004, 86:2965-2979.
8. Davis M.E., Brewster M.E. Cyclodextrin-based pharmaceutics: past, present and future. Nat. Rev. Drug Discovery 2004, 3:1023-1035.
9. Edidin M. The state of lipid rafts: from model membranes to cells. Annu. Rev. Biophys. Biomol. Struct. 2003, 32:257-283.
10. Frank D.W., Gray J.E., Weaver R.N. Cyclodextrin Nephrosis in the Rat. Am. J. Pathol. 1976, 83:367-384.
11. Frijlink H.W., Eissens A.C., Hefting N.R., Poelstra K., Lerk C.F., Meijer D.K. The effect of parenterally administered cyclodextrins on cholesterol levels in the rat. Pharm. Res. 1991, 8:9-16.
12. Galbiati F., Razani B., Lisanti M.P. Emerging themes in lipid rafts and caveolae. Cell 2001, 106:403-411.
13. Gould S., Scott R.C. 2-Hydroxypropyl-beta-cyclodextrin (HP-beta-CD): a toxicology review. Food Chem. Toxicol. 2005, 43:1451-1459.
14. Han Y.H., Kim S.Z., Kim S.H., Park W.H. Arsenic trioxide inhibits growth of As4.1 juxtaglomerular cells via cell cycle arrest and caspase-independent apoptosis. Am. J. Physiol. Renal. Physiol. 2007, 293:F511-520.
15. Kiss T., Fenyvesi F., Bácskay I., Váradi J., Fenyvesi E., Iványi R., Szente L., Tósaki A., Vecsernyés M. Evaluation of the cytotoxicity of beta-cyclodextrin derivatives: evidence for the role of cholesterol extraction. Eur. J. Pharm. Sci. 2010, 40:376-380.
16. Kiss T., Fenyvesi F., Pasztor N., Feher P., Varadi J., Kocsan R., Szente L., Fenyvesi E., Szabo G., Vecsernyes M., Bacskay I. Cytotoxicity of different types of methylated β-cyclodextrins and ionic derivatives. Pharmazie 2007, 62:557-558.
17. Kline M.A., O'Connor Butler E.S., Hinzey A., Sliman S., Kotha S.R., Marsh C.B., Uppu R.M., Parinandi N.L. A simple method for effective and safe removal of membrane cholesterol from lipid rafts in vascular endothelial cells: implications in oxidant-mediated lipid signaling. Methods Mol. Biol. 2010, 610:201-211.
18. Legrand C., Bour J.M., Jacob C., Capiaumont J., Martial A., Marc A., et al. Lactate dehydrogenase (LDH) activity of the number of dead cells in the medium of cultured eukaryotic cells as marker. J. Biotechnol. 1992, 25:231-243.
19. Luke D.R., Tomaszewski K., Damle B., Schlamm H.T. Review of the basic and clinical pharmacology of sulfobutylether-beta-cyclodextrin (SBECD). J. Pharm. Sci. 2010, 99:3291-3301.
20. Matilainen L., Toropainen T., Vihola H., Hirvonen J., Järvinen T., Jarho P., Järvinen K. In vitro toxicity and permeation of cyclodextrins in Calu-3 cells. J. Control Release 2008, 126:10-16.
21. Motoyama K., Kameyama K., Onodera R., Araki N., Hirayama F., Uekama K., Arima H. Involvement of PI3K-Akt-Bad pathway in apoptosis induced by 2,6-di-O-methyl-β-cyclodextrin, not 2-6-di-O-methyl-α-cyclodextrin, through cholesterol depletion from lipid rafts on plasma membranes in cells. Eur. J. Pharm. Sci. 2009, 38:249-261.
22. Motoyama K., Toyodome H., Onodera R., Irie T., Hirayama F., Uekama K., Arima H. Involvement of lipid rafts of rabbit red blood cells in morphological changes induced by methylated β-cyclodextrins. Biol Pharm Bull 2009, 32:700-705.
23. Mukherjee S., Zha X., Tabas I., Maxfield F.R. Cholesterol distribution in living cells: Fluorescence imaging using dehydroergosterol as a fluorescent cholesterol analog. Biophys. J. 1998, 75:1915-1925.
24. Nagase Y., Arima H., Wada K., Sugawara T., Satoh H., Hirayama F., Uekama K. Inhibitory effect of sulfobutyl ether beta-cyclodextrin on DY-9760e-induced cellular damage: in vitro and in vivo studies. J. Pharm. Sci. 2003, 92:2466-2474.
25. Ono N., Arima H., Hirayama F., Uekama K. A moderate interaction of maltosyl-α-cyclodextrin with Caco-2 cells in comparison with the parent cyclodextrin. Biol. Pharm. Bull 2001, 24:395-402.
26. Perrin J.H., Field F.P., Hansen D.A., Mufson R.A., Torosian G. Beta-Cyclodextrin as an aid to peritoneal dialysis. Renal toxicity of beta-cyclodextrin in the rat. Res. Commun. Chem. Pathol. Pharmacol. 1978, 19:373-376.
27. Rajewski R.A., Stella V.J. Pharmaceutical application of cyclodextrins. 2. In vivo drug delivery. J Pharm Sci 1996, 85:1142-1169.
28. Rajewski R.A., Traiger G., Bresnahan J., Jaberaboansari P., Stella V.J., Thompson D.O. Preliminary safety evaluation of parenterally administered sulfoalkyl ether b-cyclodextrin derivatives. J. Pharm. Sci. 1995, 84:927-932.
29. Ren, Y., Ma, X.Q., Yu, S.Q., Sun, X.D., 2009. Hydroxypropyl-Sulfobutyl- β-Cyclodextrin, the preparation method, the analytical method and the pharmaceutical application thereof. United States Application US20090012042. http://www.freepatentsonline.com.
30. Rosenbaum A.I., Zhang G.T., Warren J.D., Maxfield F.R. Endocytosis of beta-cyclodextrins is responsible for cholesterol reduction in Niemann-Pick type C mutant cells. Proc. Natl. Acad. Sci. USA 2010, 107:82-5477.
31. Rothblat H.G., De la Llera-Moya M., Atger V., Kellner-Weibel G., Williams D.L., Phillips M.C. Cell cholesterol efflux: integration of old and new observations provides new insights. J. Lipid Res. 1999, 40:781-796.
32. Salem L.B., Bosquillon C., Dailey L.A., Delattre L., Martin G.P., Evrard B., Forbes B. Sparing methylation of β-cyclodextrin mitigates cytotoxicity and permeability induction in respiratory epithelial cell layers in vitro. J. Control Release 2009, 136:110-116.
33. Schönfelder U., Radestock A., Elsner P., Hipler U.C. Cyclodextrin-induced apoptosis in human keratinocytes is caspase-8 dependent and accompanied by mitochondrial cytochrome c release. Exp. Dermatol. 2006, 15:883-890.
34. Simons K., Toomre D. Lipid rafts and signal transduction. Nat. Rev. Mol. Cell Biol. 2000, 1:31-39.
35. Srichana T., Suedee R., Reanmongkol W. Cyclodextrin as a potential drug carrier insalbutamol dry powder aerosols: the in-vitro deposition and toxicity studies of the complexes. Respir. Med. 2001, 95:513-519.
36. Stella V.J., He Q. Cyclodextrins. Toxicol. Pathol. 2008, 36:30-42.
37. Szente L., Szejtli J. Highly soluble cyclodextrin derivatives: chemistry, properties, and trends in development. Adv. Drug Deliv. Rev. 1999, 36:17-28.
38. Uekama K., Hirayama F., Irie T. Cyclodextrin drug carrier systems. Chem. Rev. 1998, 98:2045-2076.
39. Uekama K., Otagiri M. Cyclodextrins in drug carrier systems. Crit. Rev. Ther. Drug Carrier. Syst. 1987, 3:1-40.
40. Wang X., Xia X., Leung A.W., Xiang J., Jiang Y., Wang P., Xu J., Yu H., Bai D., Xu C. Ultrasound induces cellular destruction of nasopharyngeal carcinoma cells in the presence of curcumin. Ultrasonics 2011, 51:165-170.
41. Ye Y., Liu J., Xu J., Sun L., Chen M., Lan M. Nano-SiO2 induces apoptosis via activation of p53 and Bax mediated by oxidative stress in human hepatic cell line. Toxicol. in Vitro 2010, 24:751-758.
42. Zhang X.L., Yang F.X., Chao X., Liu W.P., Wen S., Xu Y. Cytotoxicity evaluation of three pairs of hexabromocyclododecane (HBCD) enantiomers on Hep G2 cell. Toxicol. in Vitro 2008, 22:1520-1527.